PDS290

DEVICE2 trials

Sponsors

Psykiatrisk Center Kobenhavn, Novo Nordisk A/S

Conditions

Diabetes Mellitus, Type 2Schizophrenia

Phase 1

A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools

CompletedNCT03598621

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2018-07-23End: 2019-01-17Updated: 2020-01-09

Phase 2

Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration of metabolic state in prediabetic or diabetic patients with schizophrenia treated with the antipsychotic compounds clozapine or olanzapine?

Not yet recruitingCTIS2024-518746-24-00

Psykiatrisk Center KobenhavnSchizophrenia

Target: 104Updated: 2024-11-04